Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

Nature Immunology

Volumn 12, Issue 9, 2011, Pages 870-878

  Pallotta, Maria T ^a   Orabona, Ciriana ^a   Volpi, Claudia ^a   Vacca, Carmine ^a   Belladonna, Maria L ^a   Bianchi, Roberta ^a   Servillo, Giuseppe ^a   Brunacci, Cinzia ^a   Calvitti, Mario ^a   Bicciato, Silvio ^b   Mazza, Emilia M C ^b   Boon, Louis ^c   Grassi, Fabio ^d   Fioretti, Maria C ^a   Fallarino, Francesca ^a   Puccetti, Paolo ^a   Grohmann, Ursula ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c BIOCEROS   (Netherlands)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ARTICLE; CELL EXPANSION; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRYPTOPHAN METABOLISM;

ADAPTIVE IMMUNITY; ANIMALS; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN;

EID: 80052020183     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2077     Document Type: Article

References (50)

1. Fazekas de St Groth, B. The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity. Immunol. Today 19, 448-454 (1998). (Pubitemid 28451886)
2. Flajnik, M.F. & Kasahara, M. Origin and evolution of the adaptive immune system: genetic events and selective pressures. Nat. Rev. Genet. 11, 47-59 (2010).
3. Grohmann, U. & Bronte, V. Control of immune response by amino acid metabolism. Immunol. Rev. 236, 243-264 (2010).
4. Jeffery, C.J. Moonlighting proteins-an update. Mol. Biosyst. 5, 345-350 (2009).
5. Forouhar, F. et al. Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA 104, 473-478 (2007). (Pubitemid 46123050)
6. Ball, H.J., Yuasa, H.J., Austin, C.J., Weiser, S. & Hunt, N.H. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 41, 467-471 (2009).
7. Metz, R. et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan. Cancer Res. 67, 7082-7087 (2007). (Pubitemid 47206533)
8. Mellor, A.L. & Munn, D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774 (2004). (Pubitemid 39336293)
9. Puccetti, P. & Grohmann, U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation. Nat. Rev. Immunol. 7, 817-823 (2007). (Pubitemid 47480306)
10. Grohmann, U., Fallarino, F. & Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003). (Pubitemid 36555962)
11. Romani, L. et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451, 211-215 (2008).
12. Belladonna, M.L. et al. Cutting edge: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 181, 5194-5198 (2008).
13. Belladonna, M.L., Orabona, C., Grohmann, U. & Puccetti, P. TGF-β and kynurenines as the key to infectious tolerance. Trends Mol. Med. 15, 41-49 (2009).
14. Irla, M. et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity. J. Exp. Med. 207, 1891-1905 (2010).
15. Matta, B.M., Castellaneta, A. & Thomson, A.W. Tolerogenic plasmacytoid DC. Eur. J. Immunol. 40, 2667-2676 (2010).
16. Lande, R. & Gilliet, M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann. NY Acad. Sci. 1183, 89-103 (2010).
17. Swiecki, M. & Colonna, M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 234, 142-162 (2010).
18. Huang, L., Baban, B., Johnson, B.A. III & Mellor, A.L. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int. Rev. Immunol. 29, 133-155 (2010).
19. Orabona, C. et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 5, 1134-1142 (2004). (Pubitemid 39549627)
20. Grohmann, U. et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat. Med. 13, 579-586 (2007). (Pubitemid 46828479)
21. Neel, B.G., Gu, H. & Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284-293 (2003). (Pubitemid 36776291)
22. Billadeau, D.D. & Leibson, P.J. ITAMs versus ITIMs: striking a balance during cell regulation. J. Clin. Invest. 109, 161-168 (2002). (Pubitemid 34083734)
23. Ravetch, J.V. & Lanier, L.L. Immune inhibitory receptors. Science 290, 84-89 (2000).
24. Sweeney, M.C. et al. Decoding protein-protein interactions through combinatorial chemistry: sequence specificity of SHP-1, SHP-2, and SHIP SH2 domains. Biochemistry 44, 14932-14947 (2005). (Pubitemid 41612272)
25. Orr, S.J. et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 109, 1061-1068 (2007). (Pubitemid 46220652)
26. Orr, S.J. et al. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J. Biol. Chem. 282, 3418-3422 (2007). (Pubitemid 47084418)
27. Orabona, C. et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. USA 105, 20828-20833 (2008).
28. Williams, J.C., Wierenga, R.K. & Saraste, M. Insights into Src kinase functions: structural comparisons. Trends Biochem. Sci. 23, 179-184 (1998). (Pubitemid 28261036)
29. Daëron, M., Jaeger, S., Du Pasquier, L. & Vivier, E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol. Rev. 224, 11-43 (2008).
30. An, H. et al. Phosphatase SHP-1 promotes TLR-and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat. Immunol. 9, 542-550 (2008). (Pubitemid 351560523)
31. Hoshino, K. et al. IκB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature 440, 949-953 (2006).
32. Tas, S.W. et al. Noncanonical NF-κB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 110, 1540-1549 (2007). (Pubitemid 47443970)
33. Orabona, C. et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 107, 2846-2854 (2006).
34. Puccetti, P. On watching the watchers: IDO and type I/II IFN. Eur. J. Immunol. 37, 876-879 (2007). (Pubitemid 46925324)
35. Taylor, M.W. & Feng, G.S. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5, 2516-2522 (1991). (Pubitemid 21905800)
36. Munn, D.H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998). (Pubitemid 28406294)
37. Grohmann, U. et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3, 1097-1101 (2002). (Pubitemid 35363664)
38. Fallarino, F. et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206-1212 (2003). (Pubitemid 37547898)
39. Fallarino, F. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752-6761 (2006). (Pubitemid 43787857)
40. Mezrich, J.D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190-3198 (2010).
41. Abu-Dayyeh, I. et al. Identification of key cytosolic kinases containing evolutionarily conserved kinase tyrosine-based inhibitory motifs (KTIMs). Dev. Comp. Immunol. 34, 481-484 (2010).
42. Grohmann, U. et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med. 198, 153-160 (2003). (Pubitemid 36870195)
43. Fallarino, F. et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 183, 6303-6312 (2009).
44. Fallarino, F. et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat. Med. 16, 897-902 (2010).
45. Orabona, C. et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J. Immunol. 174, 6582-6586 (2005). (Pubitemid 40705617)
46. Belladonna, M.L. et al. IL-23 neutralization protects mice from Gram-negative endotoxic shock. Cytokine 34, 161-169 (2006). (Pubitemid 44038571)
47. Belladonna, M.L. et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168, 5448-5454 (2002). (Pubitemid 34556122)
48. Bisognin, A. et al. A-MADMAN: annotation-based microarray data meta-analysis tool. BMC Bioinformatics 10, 201-211 (2009).
49. Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E. & Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312-319 (2005). (Pubitemid 40460560)
50. Grohmann, U. et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J. Immunol. 171, 2581-2587 (2003). (Pubitemid 37025569)